Antiviral effect of mefloquine on feline calicivirus in vitro.
Feline calicivirus (FCV) is an important viral pathogen of domestic cats causing clinical signs ranging from mild to severe oral ulceration or upper respiratory tract disease through to a severe fatal systemic disease. Current therapeutic options are limited, with no direct acting antivirals available for treatment. This study screened a panel of 19 compounds for potential antiviral activity against FCV strain F9 and recent field isolates in vitro. Using a resazurin-based cytopathic effect (CPE) inhibition assay, mefloquine demonstrated a marked inhibitory effect on FCV induced CPE, albeit with a relatively low selectivity index. Orthogonal assays confirmed inhibition of CPE was associated with a significant reduction in viral replication. Mefloquine exhibited a strong inhibitory effect against a panel of seven recent FCV isolates from Australia, with calculated IC50 values for the field isolates approximately 50% lower than against the reference strain FCV F9. In vitro combination therapy with recombinant feline interferon-ω, a biological response modifier currently registered for the treatment of FCV, demonstrated additive effects with a concurrent reduction in the IC50 of mefloquine. These results are the first report of antiviral effects of mefloquine against a calicivirus and support further in vitro and in vivo evaluation of this compound as an antiviral therapeutic for FCV.
Faculty of Veterinary Science, Building B14, The University of Sydney, Sydney, NSW 2006, Australia. Electronic address: phillip.mcdonagh@sydney.edu.au.
Phillip
P
McDonagh
Faculty of Veterinary Science, Building B19, The University of Sydney, Sydney, NSW 2006, Australia. Electronic address: paul.sheehy@sydney.edu.au.
Paul A
PA
Sheehy
Faculty of Veterinary Science, Building B03, The University of Sydney, Sydney, NSW 2006, Australia. Electronic address: anne.fawcett@sydney.edu.au.
Anne
A
Fawcett
Faculty of Veterinary Science, Building B14, The University of Sydney, Sydney, NSW 2006, Australia. Electronic address: jacqui.norris@sydney.edu.au.
Jacqueline M
JM
Norris
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D001315:Australia; D017250:Caliciviridae Infections / Q000188:drug therapy / Q000662:veterinary*; D017927:Calicivirus, Feline / Q000187:drug effects*; D002371:Cat Diseases / Q000188:drug therapy* / Q000821:virology*; D002415:Cats; D004359:Drug Therapy, Combination / Q000662:veterinary; D066298:In Vitro Techniques / Q000662:veterinary; D020128:Inhibitory Concentration 50; D007370:Interferon Type I / Q000494:pharmacology; D015767:Mefloquine / Q000494:pharmacology*; D010078:Oxazines; D014765:Viral Vaccines / Q000008:administration & dosage; D014966:Xanthenes
D000998:Antiviral Agents; D007370:Interferon Type I; D010078:Oxazines; D014765:Viral Vaccines; D014966:Xanthenes; C063743:interferon omega 1; C005843:resazurin; D015767:Mefloquine
Antiviral; Cats; Feline calicivirus; Mefloquine